SparingVision

SparingVision is a biotech company in Paris, France, founded in 2016. It has raised $71.0M across 2 rounds, most recently a Series B in September 2022.

Translating Pioneering Science into Vision-Saving Treatments

Employees
11–50
Founded
2016
Total Funding
$71.0M
Last Round
Series BSep 2022
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 7 investors for this company. The full record is or through the API.

About

SparingVision is a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. The company is going beyond single gene correction therapies to deliver new treatments to patients affected by blinding retinal diseases, regardless of genetic cause. Its lead pipeline targets Retinitis Pigmentosa, a group of inherited retinal diseases that is a leading cause of blindness globally, where current treatment approaches are not applicable to all patients.

Summary

It lists 11–50 employees. It has raised $71.0M in total across 2 rounds, most recently a Series B round in Sep 2022. Investors include Jeito Capital, UPMC Enterprises and 4BIO Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BSep 2022
EUR 75.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
CertaraIPO

Global biosimulation software and services company accelerating drug development for 2,000+ bioph...

Radnor, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$1.3BDec 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SparingVision on Indexed.vc
<a href="https://indexed.vc/companies/sparingvision"><img src="https://indexed.vc/api/badge/company/sparingvision" alt="SparingVision on Indexed.vc" width="260" height="76" /></a>